| Increased mTOR activation in idiopathic multicentric Castleman disease DJ Arenas, K Floess, D Kobrin, RAL Pai, MB Srkalovic, MA Tamakloe, ... Blood, The Journal of the American Society of Hematology 135 (19), 1673-1684, 2020 | 62 | 2020 |
| Treatments administered to the first 9152 reported cases of COVID-19: a systematic review DC Fajgenbaum, JS Khor, A Gorzewski, MA Tamakloe, V Powers, ... Infectious diseases and therapy 9, 435-449, 2020 | 55 | 2020 |
| Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion R Choa, J Tohyama, S Wada, H Meng, J Hu, M Okumura, RM May, ... Science 373 (6554), eabd2893, 2021 | 48 | 2021 |
| Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease RAL Pai, AS Japp, M Gonzalez, RF Rasheed, M Okumura, D Arenas, ... JCI insight 5 (9), 2020 | 47 | 2020 |
| Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease SK Pierson, S Shenoy, AB Oromendia, AM Gorzewski, RA Langan Pai, ... Blood advances 5 (17), 3445-3456, 2021 | 30 | 2021 |
| The role of thymic stromal lymphopoietin (TSLP) in protection from type II diabetes R Choa, S Wada, H Meng, RAL Pai, M Okumura, J Tohyama, A Nace, ... The Journal of Immunology 204 (1_Supplement), 145.8-145.8, 2020 | 3 | 2020 |
| Identifying And Targeting Mechanisms Of Immune Cell Activation In Imcd-Tafro RAL Pai University of Pennsylvania, 2021 | | 2021 |
| A Type I interferon response is associated with increased mTOR activation in idiopathic multicentric Castleman disease RAL Pai, AS Japp, M Gonzalez, RF Rasheed, M Okumura, D Arenas, ... The Journal of Immunology 204 (1_Supplement), 145.7-145.7, 2020 | | 2020 |
| Treatments administered to the first 9,152 reported cases of COVID19: a systematic review (preprint) DC Fajgenbaum, JS Khor, A Gorzewski, MA Tamakloe, V Powers, ... | | 2020 |
